BR112014015322A8 - compostos e composições para inibir a interação de bcl2 com parceiros de ligação - Google Patents
compostos e composições para inibir a interação de bcl2 com parceiros de ligaçãoInfo
- Publication number
- BR112014015322A8 BR112014015322A8 BR112014015322A BR112014015322A BR112014015322A8 BR 112014015322 A8 BR112014015322 A8 BR 112014015322A8 BR 112014015322 A BR112014015322 A BR 112014015322A BR 112014015322 A BR112014015322 A BR 112014015322A BR 112014015322 A8 BR112014015322 A8 BR 112014015322A8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- bcl
- interaction
- formula
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
abstract the present invention relates to compounds of formula i: in which r1, r2, r3 and r4 are as defined in the summary of the invention. compounds of formula i are capable of disrupting the bcl-2 interations with proteins containing a bh3 domain. disrupting this interaction can restore the anti-apoptotic function of bcl-2 in cancer cells and tumor tissue expressing bcl-2. the invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancerous diseases. tradução do resumo resumo patente de invenção: "compostos e composições para inibir a interação de bcl2 com parceiros de ligação". a presente invenção refere-se aos compostos da fórmula i: na qual r1, r2, r3 e r4 são conforme definidos no sumário da invenção. os compostos da fórmula i são capazes de interferir nos processos de interação entre bcl-2 e proteínas contendo um domínio bh3. a interferência nesta interação pode restaurar a função apoptótica de bcl-2 em células cancerosas e no tecido tumoral que expressa bcl-2. a invenção provê ainda um processo para o preparo de compostos da invenção, de preparados farmacêuticos que compreendem tais compostos e de métodos para o uso de tais compostos no tratamento de doenças cancerosas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579724P | 2011-12-23 | 2011-12-23 | |
PCT/US2012/069270 WO2013096059A1 (en) | 2011-12-23 | 2012-12-12 | Compounds for inhibiting the interaction of bcl2 with binding partners |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014015322A2 BR112014015322A2 (pt) | 2017-06-13 |
BR112014015322A8 true BR112014015322A8 (pt) | 2017-06-13 |
Family
ID=47429052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014015322A BR112014015322A8 (pt) | 2011-12-23 | 2012-12-12 | compostos e composições para inibir a interação de bcl2 com parceiros de ligação |
Country Status (11)
Country | Link |
---|---|
US (1) | US9126979B2 (pt) |
EP (1) | EP2794591A1 (pt) |
JP (1) | JP2015503518A (pt) |
KR (1) | KR20140104047A (pt) |
CN (1) | CN104125954A (pt) |
AU (1) | AU2012355623A1 (pt) |
BR (1) | BR112014015322A8 (pt) |
CA (1) | CA2859869A1 (pt) |
EA (1) | EA201491264A1 (pt) |
MX (1) | MX2014007730A (pt) |
WO (1) | WO2013096059A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140107573A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
FR3008978A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
FR3008977A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3008979B1 (fr) | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3008976A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
CA3073656C (en) | 2017-09-22 | 2024-03-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
SG11202004143XA (en) | 2017-11-06 | 2020-06-29 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
CN111542523B (zh) | 2017-11-24 | 2024-03-29 | 朱比连特埃皮斯科瑞有限责任公司 | 作为prmt5抑制剂的杂环化合物 |
CA3093527A1 (en) | 2018-03-13 | 2019-09-19 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
CA3098348A1 (en) | 2018-04-29 | 2019-11-07 | Beigene, Ltd. | Bcl-2 inhibitors |
CN110746355B (zh) * | 2018-07-24 | 2023-08-11 | 中国科学院上海有机化学研究所 | 一种苯基吡唑类化合物、药物组合物、其制备方法及应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
TW225528B (pt) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
DK0666868T4 (da) | 1992-10-28 | 2006-09-18 | Genentech Inc | Anvendelse af anti-VEGF-antistoffer til behandling af cancer |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US6140332A (en) | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
ATE213730T1 (de) | 1996-04-12 | 2002-03-15 | Warner Lambert Co | Umkehrbare inhibitoren von tyrosin kinasen |
DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
WO1998010121A1 (en) | 1996-09-06 | 1998-03-12 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
EP0954315A2 (en) | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CN100344627C (zh) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
CA2322157C (en) | 1998-02-25 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
BR9912938B1 (pt) | 1998-08-11 | 2011-06-28 | derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos. | |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
CA2355976C (en) | 1998-12-22 | 2012-07-17 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
CN1221262C (zh) | 1999-03-30 | 2005-10-05 | 诺瓦提斯公司 | 治疗炎性疾病的酞嗪衍生物 |
AU2001284942A1 (en) | 2000-08-16 | 2002-02-25 | Georgetown University Medical Center | Small molecule inhibitors targeted at bcl-2 |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
AU2002305769B2 (en) | 2001-05-30 | 2007-07-19 | Georgetown University | Small molecule antagonists of Bcl2 family proteins |
US20030119894A1 (en) | 2001-07-20 | 2003-06-26 | Gemin X Biotechnologies Inc. | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
MX2007002104A (es) * | 2004-08-20 | 2007-10-10 | Univ Michigan | Inhibidores de moleculas pequenas de los miembros de la familia bcl-2 anti-apoptoticos, y usos de los mismos. |
US8557812B2 (en) * | 2004-08-20 | 2013-10-15 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
EP2094672B1 (en) | 2006-11-15 | 2013-05-29 | Genentech, Inc. | Arylsulfonamide compounds |
WO2011029842A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
EA201491265A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |
CN104136428A (zh) | 2011-12-23 | 2014-11-05 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
US20140357633A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
KR20140107573A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
-
2012
- 2012-12-12 US US14/366,857 patent/US9126979B2/en not_active Expired - Fee Related
- 2012-12-12 JP JP2014549138A patent/JP2015503518A/ja active Pending
- 2012-12-12 EA EA201491264A patent/EA201491264A1/ru unknown
- 2012-12-12 KR KR1020147020549A patent/KR20140104047A/ko not_active Application Discontinuation
- 2012-12-12 EP EP12805896.3A patent/EP2794591A1/en not_active Withdrawn
- 2012-12-12 WO PCT/US2012/069270 patent/WO2013096059A1/en active Application Filing
- 2012-12-12 AU AU2012355623A patent/AU2012355623A1/en not_active Abandoned
- 2012-12-12 CA CA2859869A patent/CA2859869A1/en not_active Abandoned
- 2012-12-12 CN CN201280070505.4A patent/CN104125954A/zh active Pending
- 2012-12-12 BR BR112014015322A patent/BR112014015322A8/pt not_active Application Discontinuation
- 2012-12-12 MX MX2014007730A patent/MX2014007730A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2859869A1 (en) | 2013-06-27 |
MX2014007730A (es) | 2015-01-12 |
US9126979B2 (en) | 2015-09-08 |
KR20140104047A (ko) | 2014-08-27 |
JP2015503518A (ja) | 2015-02-02 |
WO2013096059A1 (en) | 2013-06-27 |
EP2794591A1 (en) | 2014-10-29 |
BR112014015322A2 (pt) | 2017-06-13 |
AU2012355623A1 (en) | 2014-07-17 |
US20140343093A1 (en) | 2014-11-20 |
EA201491264A1 (ru) | 2014-11-28 |
CN104125954A (zh) | 2014-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014015322A2 (pt) | compostos e composições para inibir a interação de bcl2 com parceiros de ligação | |
BR112014015339A2 (pt) | compostos para inibição da interação de bcl2 com parceiros de ligação | |
BR112014015274A2 (pt) | compostos e composições para inibição da interação de bcl2 com parceiros de ligação | |
BR112014015308A2 (pt) | compostos para inibição da interação de bcl2 com contrapartes de ligação | |
BR112014015442A2 (pt) | compostos e composições para inibir a interação de bcl2 com parceiros de ligação | |
BR112014007622A2 (pt) | inibidores de flt3 cinase macrocíclicos | |
BRPI1006115A8 (pt) | "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes". | |
BR112015014458A8 (pt) | compostos derivados de manose, seus intermediários, composição, uso e processos de preparação | |
BR112015022096A8 (pt) | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos | |
BR112015007083A2 (pt) | inibidores de histona demetilases | |
EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
BRPI0916735B8 (pt) | compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos | |
CR20180339A (es) | INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576) | |
BR112014010183B8 (pt) | Composto, composição farmacêutica, produto, e, uso de um composto | |
EA201201161A1 (ru) | Пирролопиримидины в качестве ингибиторов cdk4/6 | |
BRPI0721905B8 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
MX2020012695A (es) | Compuestos de benceno substituidos con arilo o heteroarilo. | |
BR112013009093A2 (pt) | dispersões sólidas contendo um agente indutor de apoptose | |
BR112012033402A2 (pt) | moduladores de canais de íons conforme os compostos heterocíclicos fundidos | |
BR112013002914A2 (pt) | promotores de apoptose de n-acilsulfonamida | |
EA200901138A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
BRPI0906444B8 (pt) | compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos | |
CL2013001459A1 (es) | Compuestos derivados de quinazolincarboxamida azetidina; proceso para prepararlos; composicion farmaceutica que los comprende; set (kit); y su uso para el tratamiento de enfermedades hiperproliferativas tales como cancer, inflamacion, pancreatitis o enfermedad renal, dolor, hiperplasia benigna de piel entre otras. | |
BR112014029089A2 (pt) | anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |